CareDx Highlights Latest Innovations in HLA Typing and Hematopoietic Stem Cell Transplant Chimerism Monitoring

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced its leading presence as a Diamond Level sponsor at the 48^th annual meeting of the American Society for Histocompatibility and Immunogenetics (ASHI) being held in Las Vegas, Nevada from October 24 to October 28.

“CareDx is proud to be a leading sponsor of this year’s ASHI meeting to help drive continued innovation in transplantation through our laboratory products,” said Reg Seeto, CEO and President of CareDx. “We are excited to share the latest data about our innovative, best-in-class NGS HLA typing kits and chimerism monitoring solutions for hematopoietic stem cell transplantation.”¹

CareDx will be presenting the latest data on its AlloSeq NGS¹ solutions and hosting a symposium, “Innovation Across the Pre- and Post-Transplant Journey,” on Tuesday, October 25, from 12:00 noon to 2:05 p.m. PT. Moderated by Curtis Lind, Vice President and Head of Research and Development Products at CareDx, the symposium includes the following:

• NGS-HLA for Solid Organ Transplant: The Time is Now. Cathi Murphey Half, Ph.D., HCLD/CC(ABB), A(ACHI), Director, Histocompatibility and Immunogenetics Laboratory Southwest Immunodiagnostics, Inc.
• NGS Chimerism Validation: The St. Jude Experience. Paula Arnold, Ph.D., D(ABHI), Technical Director, HLA Department of Pathology, St. Jude Children’s Research Hospital.

“I look forward to attending this year’s ASHI meeting and connecting with the HLA community to review the latest transplant innovations, including those developed by CareDx using next-generation sequencing and hybrid capture technologies,” said Cathi Murphey Half, Ph.D., HCLD/CC(ABB), A(ACHI) Director, Histocompatibility and Immunogenetics Laboratory Southwest Immunodiagnostics, Inc.

Eight scientific abstracts highlight the use of CareDx’s flagship AlloSeq Tx17¹, which offers laboratory professionals a novel method for matching transplant recipients and potential donors. The hybrid capture approach to matching is unique to CareDx and gives labs flexibility in gene content and increased robustness over other methodologies. By sequencing the HLA genes, better matches can be selected, giving transplanted organs a higher chance of long-term allograft survival.

Additionally, three abstracts highlight the validation and use of AlloSeq HCT.¹ The data will highlight the performance and potential utility of a more streamlined, sensitive approach for NGS-based engraftment monitoring and surveillance following hematopoietic stem cell transplantation.

About CareDx – The Transplant Company

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

Forward Looking Statements

This press release includes forward-looking statements related to CareDx, Inc., including statements regarding the potential benefits and results that may be achieved with CareDx’s leading presence and sponsorship in 2022 ASHI meeting (the “Meeting”), its AlloSeq products and solutions, and its presentation of the latest data on the AlloSeq products and solutions and transplant innovation at the Meeting (the “Presentation”). These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks that CareDx does not realize the expected benefits of its leading presence and sponsorship in the Meeting, its AlloSeq products and solutions, or its Presentation; general economic and market factors; and other risks discussed in CareDx’s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed by CareDx with the SEC on February 24, 2022, the quarterly report on Form 10-Q for the quarter ended March 31, 2022 filed by CareDx with the SEC on May 5, 2022, the quarterly report on Form 10-Q for the quarter ended June 30, 2022 filed by CareDx with the SEC on August 4, 2022, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.

References:

^1. AlloSeq Tx17 and AlloSeq HCT are for research use only in the United States.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221025005454/en/